Trastuzumab Emtansine: 12 agencies, 2014–2021
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 7.6 years, from 26 Feb 2014 at AWMSG (Wales) to 28 Sep 2021 at AIFA (Italy).
NYE METODER (Norway) changed its position: not recommended on 14 Aug 2017, recommended by 30 Aug 2020, after a resubmission.
No assessment is on file from TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
Nothing has been added since 2021; on this evidence the file is dormant.
7 distinct indication wordings are recorded for trastuzumab emtansine by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 20 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess trastuzumab emtansine, on 26 Feb 2014; AIFA (Italy) did not open a file until 28 Sep 2021 — a wide spread of 7.6 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 8 of 20 dated records fall in 2020 alone.
8 of the 12 agencies here assessed trastuzumab emtansine more than once, PHARMAC (New Zealand) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
trastuzumab emtansine has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for trastuzumab emtansine reads 11 recommended, 4 restricted, 2 not recommended and 2 deferred to NICE, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AIFA (Italy) | 28 Sep 2021 | «Kadcyla», in monoterapia, e' indicato per il trattamento adiuvante di pazienti adulti affetti da tumore mammario in sta… | innovative, since expired | source |
| SMC (Scotland) | 9 Nov 2020 | As a single agent, for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and / or lymph no… | accepted | source |
| AOTMIT (Poland) | 6 Nov 2020 | Kadcyla reimbursement recommendation | not recommended | source |
| ZIN (Netherlands) | 24 Sep 2020 | Pakketadvies sluisgeneesmiddel trastuzumab-emtansine (Kadcyla®) bij vroege HER2-positieve borstkanker | reimburse only after price negotiation | source |
| PHARMAC (New Zealand) | 21 Feb 2019 | HER2+ metastatic breast cancer after prior trastuzumab and a taxane | PTAC advice: No Formal Recommendation · decision reached | source |
15 further decisions for trastuzumab emtansine, across 10 agencies, are not shown here. They link to 14 further source documents.
Related molecules
- neratinib — divergent outcome (recommended vs not recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
Coverage: 20 decisions for trastuzumab emtansine from 12 agencies, 2014 to 2021. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.